We are live on ! Find out more
PSC

Piper Sandler & Co Portfolio holdings

AUM $102M
1-Year Est. Return 0.13%
This Fund
S&P 500
This Quarter Est. Return
-3.94%
1 Year Est. Return
+0.13%
3 Year Est. Return
-0.09%
5 Year Est. Return
-7.67%
10 Year Est. Return
–
AUM
$46.1M
AUM Growth
+$6.69M
Cap. Flow
-$4.54M
Cap. Flow %
-9.85%
Top 10 Hldgs %
99.92%
Holding
34
New
11
Increased
2
Reduced
2
Closed
14

Top Buys

Rank Stock Value
1
SAAS
inContact, Inc.
SAAS
+$282K
2
GILD icon
Gilead Sciences
GILD
+$162K
3
PRLB icon
Protolabs
PRLB
+$70.7K
4
WFC.PRL icon
Wells Fargo 7.5% Non Cumv Perp Conv
WFC.PRL
+$23.5K
5
KSU
Kansas City Southern
KSU
+$15.6K

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$759K
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$481K
3
VTVT icon
vTv Therapeutics
VTVT
+$435K
4
BHC icon
Bausch Health
BHC
+$201K
5
THC icon
Tenet Healthcare
THC
+$180K

Sector Composition

Rank Sector Weight
1 Healthcare 7.42%
2 Technology 0.63%
3 Industrials 0.22%
4 Consumer Discretionary 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$20.6M 44.58%
100,000
+50,000
+100% +$9.76M
XLE icon
2
PUT
State Street Energy Select Sector SPDR ETF
XLE
$39.5B
$4.95M 10.74%
160,000
+20,000
+14% +$580K
VTVT icon
3
vTv Therapeutics
VTVT
$121M
$3.18M 6.9%
15,404
-1,746
-10% -$435K
SAAS
4
DELISTED
inContact, Inc.
SAAS
$284K 0.62%
+32,000
New +$282K
GILD icon
5
Gilead Sciences
GILD
$161B
$165K 0.36%
+1,800
New +$162K
PRLB icon
6
Protolabs
PRLB
$1.86B
$84K 0.18%
+1,095
New +$70.7K
ARCT icon
7
Arcturus Therapeutics
ARCT
$157M
$73K 0.16%
1,663
– –
WFC.PRL icon
8
Wells Fargo 7.5% Non Cumv Perp Conv
WFC.PRL
$4.66B
$24K 0.05%
+20
New +$23.5K
KSU
9
DELISTED
Kansas City Southern
KSU
$17K 0.04%
+200
New +$15.6K
VCRA
10
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$7K 0.02%
+554
New +$7.67K
ASNA
11
DELISTED
Ascena Retail Group, Inc.
ASNA
$5K 0.01%
+24
New +$4.23K
ZTS icon
12
Zoetis
ZTS
$31.6B
$2K ﹤0.01%
+52
New +$2.21K
LDRH
13
DELISTED
LDR HOLDINGS CORP COM STK
LDRH
$2K ﹤0.01%
81
-1,118
-93% -$23.4K
NTRA icon
14
Natera
NTRA
$37.5B
$1K ﹤0.01%
+96
New +$812
OXFD
15
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1K ﹤0.01%
65
– –
BHC icon
16
Bausch Health
BHC
$1.65B
– –
-1,976
Closed -$201K
BLUE
17
DELISTED
bluebird bio
BLUE
– –
-174
Closed -$145K
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-1,385
Closed -$145K
COLL icon
19
Collegium Pharmaceutical
COLL
$1.14B
– –
-599
Closed -$16K
INCY icon
20
Incyte
INCY
$23.5B
– –
-201
Closed -$22K
LULU icon
21
lululemon athletica
LULU
$13B
– –
-3,353
Closed -$176K
TEVA icon
22
Teva Pharmaceuticals
TEVA
$35.9B
– –
-11,559
Closed -$759K
THC icon
23
Tenet Healthcare
THC
$20.1B
– –
-5,929
Closed -$180K
VRTX icon
24
Vertex Pharmaceuticals
VRTX
$121B
– –
-3,825
Closed -$481K
CMRX
25
DELISTED
Chimerix, Inc.
CMRX
– –
-22
Closed –
1
2

Similar funds

LIC
Laurus Investment Counsel Toronto, Canada $102M AUM 0% 1-Year Est. Return
SAM
Stembrook Asset Management Red Bank, New Jersey $102M AUM
FHM
Framtiden Holdings Management Chicago, Illinois $102M AUM
IOOF
Independent Order of Foresters Toronto, Ontario, Canada $102M AUM 16.7% 1-Year Est. Return
BU
Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return
MBAML
Marble Bar Asset Management LLP London $102M AUM
BHFP
Blom & Howell Financial Planning Modesto, California $102M AUM
IWA
Independent Wealth Advisors Cary, North Carolina $102M AUM

Piper Sandler & Co's Q1 2016 Portfolio in Review

As of Q1 2016, Piper Sandler & Co held 34 positions worth $46.1M, up 17% from $39.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Piper Sandler & Co withdrew a net $4.54M in Q1 2016, closing 14 positions and reducing 2 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $759K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.4% of assets, down from 17% a quarter earlier, followed by Technology and Industrials.

Against the trend, Piper Sandler & Co opened a new position in inContact, Inc. worth $284K.

  • Piper Sandler & Co's largest Q1 2016 buy was inContact, Inc.: 32,000 shares worth $284K.
  • Piper Sandler & Co's biggest Q1 2016 reduction was vTv Therapeutics, cutting an estimated $435K.
  • Piper Sandler & Co fully exited Teva Pharmaceuticals in Q1 2016, selling an estimated $759K.
  • Piper Sandler & Co's ten largest holdings make up 100% of its $46.1M portfolio in Q1 2016.
  • Piper Sandler & Co opened 11 new positions and closed 14 in Q1 2016.
  • Piper Sandler & Co's portfolio value rose 17% quarter-over-quarter to $46.1M.

Based on Piper Sandler & Co's 13F filing for Q1 2016, filed 16 May 2016.